Production & Sales

Chiesi to acquire licensing rights to Santhera’s LHON drug Raxone

Italy-based Chiesi Farmaceutici (Chiesi Group) has agreed to buy the licensing rights of Raxone (idebenone), an approved drug for Leber's hereditary optic neuropathy (LHON) in Europe, from Swiss pharma company Santhera Pharmaceuticals in a deal worth up to CHF105m (£82.5m).

Nektar Therapeutics launches Inheris Biopharma

Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company.

WuXi Biologics signed letter of intent for long-term vaccine manufacturing contract

WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has entered into a strategic partnership letter of intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.

Catalent wraps up $1.2bn acquisition of gene therapy CDMO Paragon

Catalent has wrapped up its $1.2bn acquisition of Maryland-based gene therapy contract development and manufacturing organisation (CDMO) Paragon Bioservices.

Thermo Fisher Scientific to acquire manufacturing site in Cork, Ireland, from GSK

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc (NYSE: GSK) for approximately €90 million in cash.

Exelixis’ collaborator Daiichi Sankyo launches MINNEBRO (Esaxerenone) tablets in Japan

Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.

Pfizer opens new biologics clinical manufacturing facility in Massachusetts

Pfizer has announced the opening of a new 175,000 square-foot manufacturing facility in Andover, Massachusetts.

Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn

Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn.

Teva Pharmaceuticals USA recalls Losartan Potassium 25mg and 100mg Tablets USP sold exclusively to Golden State Medical Supply

Teva Pharmaceuticals USA has initiated a voluntary recall in the US, to the patient level, of 35 lots of bulk Losartan Potassium USP Tablets (6 lots of 25 mg strength and 29 lots of 100 mg strength).